298 related articles for article (PubMed ID: 30246215)
1. Effect of levodopa on frontal-subcortical and posterior cortical functioning in patients with Parkinson's disease.
Gul A; Yousaf J
Singapore Med J; 2019 Aug; 60(8):414-417. PubMed ID: 30246215
[TBL] [Abstract][Full Text] [Related]
2. Levodopa may affect cortical excitability in Parkinson's disease patients with cognitive deficits as revealed by reduced activity of cortical sources of resting state electroencephalographic rhythms.
Babiloni C; Del Percio C; Lizio R; Noce G; Lopez S; Soricelli A; Ferri R; Pascarelli MT; Catania V; Nobili F; Arnaldi D; Famà F; Orzi F; Buttinelli C; Giubilei F; Bonanni L; Franciotti R; Onofrj M; Stirpe P; Fuhr P; Gschwandtner U; Ransmayr G; Fraioli L; Parnetti L; Farotti L; Pievani M; D'Antonio F; De Lena C; Güntekin B; Hanoğlu L; Yener G; Emek-Savaş DD; Triggiani AI; Taylor JP; McKeith I; Stocchi F; Vacca L; Frisoni GB; De Pandis MF
Neurobiol Aging; 2019 Jan; 73():9-20. PubMed ID: 30312790
[TBL] [Abstract][Full Text] [Related]
3. Levodopa influences striatal activity but does not affect cortical hyper-activity in Parkinson's disease.
Martinu K; Degroot C; Madjar C; Strafella AP; Monchi O
Eur J Neurosci; 2012 Feb; 35(4):572-83. PubMed ID: 22304628
[TBL] [Abstract][Full Text] [Related]
4. Parkinson's disease-cognitive rating scale: a new cognitive scale specific for Parkinson's disease.
Pagonabarraga J; Kulisevsky J; Llebaria G; García-Sánchez C; Pascual-Sedano B; Gironell A
Mov Disord; 2008 May; 23(7):998-1005. PubMed ID: 18381647
[TBL] [Abstract][Full Text] [Related]
5. Electroencephalographic lateralization, clinical correlates and pharmacological response in untreated Parkinson's disease.
Mostile G; Nicoletti A; Dibilio V; Luca A; Pappalardo I; Giuliano L; Cicero CE; Sciacca G; Raciti L; Contrafatto D; Bruno E; Sofia V; Zappia M
Parkinsonism Relat Disord; 2015 Aug; 21(8):948-53. PubMed ID: 26096796
[TBL] [Abstract][Full Text] [Related]
6. Levodopa and the feedback process on set-shifting in Parkinson's disease.
Au WL; Zhou J; Palmes P; Sitoh YY; Tan LC; Rajapakse JC
Hum Brain Mapp; 2012 Jan; 33(1):27-39. PubMed ID: 21438075
[TBL] [Abstract][Full Text] [Related]
7. [Dynamics of cognitive impairments during L-dopa therapy in Parkinson's disease].
Ismailova SB; Prokopenko SV; Pokhabov DV; Mosaleva EI; Alekseenko PV; Zhumzhanov IM
Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(7):36-41. PubMed ID: 34460155
[TBL] [Abstract][Full Text] [Related]
8. Frontal-subcortical defects correlate with task switching deficits in Parkinson`s disease.
Gul A; Yousaf J; Ahmad H
Neurosciences (Riyadh); 2017 Jul; 22(3):224-227. PubMed ID: 28678219
[TBL] [Abstract][Full Text] [Related]
9. Effect of levodopa on cognitive function in Parkinson's disease with and without dementia and dementia with Lewy bodies.
Molloy SA; Rowan EN; O'Brien JT; McKeith IG; Wesnes K; Burn DJ
J Neurol Neurosurg Psychiatry; 2006 Dec; 77(12):1323-8. PubMed ID: 16952917
[TBL] [Abstract][Full Text] [Related]
10. Levodopa improves motor function without impairing cognition in mild non-demented Parkinson's disease patients. Parkinson Study Group.
Growdon JH; Kieburtz K; McDermott MP; Panisset M; Friedman JH
Neurology; 1998 May; 50(5):1327-31. PubMed ID: 9595982
[TBL] [Abstract][Full Text] [Related]
11. Cognitive and cortical thinning patterns of subjective cognitive decline in patients with and without Parkinson's disease.
Hong JY; Yun HJ; Sunwoo MK; Ham JH; Lee JM; Sohn YH; Lee PH
Parkinsonism Relat Disord; 2014 Sep; 20(9):999-1003. PubMed ID: 25001316
[TBL] [Abstract][Full Text] [Related]
12. Levodopa Effect and Motor Function in Late Stage Parkinson's Disease.
Rosqvist K; Horne M; Hagell P; Iwarsson S; Nilsson MH; Odin P
J Parkinsons Dis; 2018; 8(1):59-70. PubMed ID: 29480220
[TBL] [Abstract][Full Text] [Related]
13. A dopamine agonist, pramipexole, and cognitive functions in Parkinson's disease.
Relja M; Klepac N
J Neurol Sci; 2006 Oct; 248(1-2):251-4. PubMed ID: 16797593
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
[TBL] [Abstract][Full Text] [Related]
15. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease.
Cools R
Neurosci Biobehav Rev; 2006; 30(1):1-23. PubMed ID: 15935475
[TBL] [Abstract][Full Text] [Related]
16. L-dopa medication in Parkinson's disease restores activity in the motor cortico-striatal loop but does not modify the cognitive network.
Jubault T; Monetta L; Strafella AP; Lafontaine AL; Monchi O
PLoS One; 2009 Jul; 4(7):e6154. PubMed ID: 19584921
[TBL] [Abstract][Full Text] [Related]
17. l-DOPA changes ventral striatum recruitment during motor sequence learning in Parkinson's disease.
Kwak Y; Müller ML; Bohnen NI; Dayalu P; Seidler RD
Behav Brain Res; 2012 Apr; 230(1):116-24. PubMed ID: 22343069
[TBL] [Abstract][Full Text] [Related]
18. Levodopa-sensitive, dynamic changes in effective connectivity during simultaneous movements in Parkinson's disease.
Palmer SJ; Eigenraam L; Hoque T; McCaig RG; Troiano A; McKeown MJ
Neuroscience; 2009 Jan; 158(2):693-704. PubMed ID: 18722512
[TBL] [Abstract][Full Text] [Related]
19. L-Dopa response to Cortical Dysfunctions, health related quality of life and Fatigue Severity in Idiopathic Parkinson's disease.
Gul A; Yousaf J
Pak J Med Sci; 2018; 34(4):1014-1018. PubMed ID: 30190772
[TBL] [Abstract][Full Text] [Related]
20. L-dopa treatment increases oscillatory power in the motor cortex of Parkinson's disease patients.
Cao C; Li D; Zhan S; Zhang C; Sun B; Litvak V
Neuroimage Clin; 2020; 26():102255. PubMed ID: 32361482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
